Perioperative Immunotherapy More Than Doubles Event-Free Survival in Early-Stage Lung Cancer
Final Phase 3 IMpower030 results show that perioperative atezolizumab plus chemotherapy extended median event-free survival to 62.8 months versus 34.9 ...
Tag: innovative therapies for resectable lung cancer
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!